October 20, 2025Clarametyx Biosciences Strengthens Leadership Team to Accelerate Pipeline and Corporate Development ProgressRead More October 16, 2025Clarametyx Biosciences Announces Completion of Enrollment in Phase 2a Study of CMTX-101 in Cystic FibrosisRead More August 4, 2025Clarametyx Biosciences Announces FDA Grant Of Fast Track And Qualified Infectious Disease Product Designations For CMTX-101Read More June 16, 2025Clarametyx Biosciences Announces Positive Interim Analysis in Phase 2a Study Evaluating CMTX-101 for Infections Associated with Cystic FibrosisRead More May 2, 2025CincyTech Invests in Clarametyx to Advance Breakthrough Anti-Biofilm Therapies for Chronic Respiratory DiseaseRead More January 28, 2025Clarametyx Biosciences Announces Investment by Kineticos AMR Accelerator FundRead More January 7, 2025Clarametyx Biosciences Awarded a Multi-Phased Agreement with CARB-X to Accelerate Anti-Biofilm Vaccine to Prevent Bacterial InfectionsRead More November 19, 2024Clarametyx Bioscience Recognized as “Infectious Disease Innovation of the Year” In 2024 BioTech Breakthrough AwardsRead More October 17, 2024Clarametyx Biosciences Announces Progress on Study of Antibody Therapy CMTX-101 For Infections Associated With Cystic FibrosisRead More
